IL1R2 blockade alleviates immunosuppression and potentiates anti-PD-1 efficacy in triple-negative breast cancer.
Xia J, Zhang L, Peng X, Tu J, Li S, He X, Li F, Qiang J, Dong H, Deng Q, Liu C, Xu J, Zhang R, Liu Q, Hu G, Liu C, Jiang YZ, Shao ZM, Chen C, Liu S.
Xia J, et al. Among authors: he x.
Cancer Res. 2024 Apr 24. doi: 10.1158/0008-5472.CAN-23-3429. Online ahead of print.
Cancer Res. 2024.
PMID: 38657120